In a more recent study, the same authors reported that 150 NPM1-mut AML patients achieved CR following induction chemotherapy: patients with CHIP mutations, such as DNMT3A, TET2, ASXL1, IDH1, IDH2, and SRSF2, had a frequency of relapse and a probability of OS comparable to that observed for NPM1-mut without co-mutations at remission; in contrast, patients with mutations that were not CHIP related, such as FLT3-ITD, FLT3-TKD, GATA2, NRAS, PTPN11, WT1, TP53, and RUNX1, persistent at remission or acquired at relapse, had an increased probability of relapse and a poor prognosis [27]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.